{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:42:51Z","timestamp":1765374171923,"version":"3.46.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.transci.2025.104244","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T03:22:09Z","timestamp":1756437729000},"page":"104244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mob-Marly: A Latin American experience in hematopoietic stem cell mobilization for autologous transplantation"],"prefix":"10.1016","volume":"64","author":[{"given":"\u00d3scar","family":"Pe\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licet","family":"Villamizar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Charry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Pedraza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Cid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2025.104244_bib1","doi-asserted-by":"crossref","unstructured":"Philip Thierry, Guglielmi Cesare, Hagenbeek Anton, Somers Renier, Van Der Lelie Hans, Bron Dominique, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-sensitive Non-Hodgkin\u00b4s Lymphoma. Vol. 7. 1995 Dec.","DOI":"10.1056\/NEJM199512073332305"},{"issue":"9323","key":"10.1016\/j.transci.2025.104244_bib2","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemo sensitive Hodgkin\u2019s disease: a randomized trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2025.104244_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cells12242855","article-title":"Autologous stem cell transplant in Hodgkin\u2019s and Non-Hodgkin\u2019s lymphoma, multiple myeloma, and AL amyloidosis","volume":"12","author":"Alnasser","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.transci.2025.104244_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies","volume":"16","author":"Parrondo","year":"2020","journal-title":"JCO Oncol Pr [Internet]"},{"key":"10.1016\/j.transci.2025.104244_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100771","article-title":"Getting blood out of a stone: identification and management of patients with poor hematopoietic cell mobilization","volume":"47","author":"Chen","year":"2021","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.transci.2025.104244_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","article-title":"Cost-effectiveness analysis of a Risk-Adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization","volume":"19","author":"Micallef","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.transci.2025.104244_bib7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/bmt.2010.236","article-title":"Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention","volume":"46","author":"Sinha","year":"2011","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104244_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.transci.2025.104244_bib9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bbmt.2011.10.002","article-title":"Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections","volume":"18","author":"Gambell","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.transci.2025.104244_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04107.x","article-title":"Mobilization of CD34+ cells in elderly patients (\u2265 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen","volume":"120","author":"Morris","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.transci.2025.104244_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ajh.21400","article-title":"Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma","volume":"84","author":"Hosing","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2025.104244_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.blre.2017.11.002","article-title":"Diabetes mellitus as a poor mobilizer condition","volume":"32","author":"Fadini","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.transci.2025.104244_bib13","doi-asserted-by":"crossref","unstructured":"Mohty M., H\u00fcbel K., Kr\u00f6ger N., Aljurf M., Apperley J., Basak G.W., 2014. Autologous Hematopoietic Stem Cell Mobilization in Multiple Myeloma and Lymphoma Patients: A Position Statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 49. Nature Publishing Group, 865872.","DOI":"10.1038\/bmt.2014.39"},{"issue":"1","key":"10.1016\/j.transci.2025.104244_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.transci.2009.05.011","article-title":"Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions","volume":"41","author":"Perseghin","year":"2009","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.transci.2025.104244_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/trf.13868","article-title":"How do we mobilize and collect autologous peripheral blood stem cells?","volume":"57","author":"Yuan","year":"2017","journal-title":"Transfus (Paris)"},{"key":"10.1016\/j.transci.2025.104244_bib16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/10428190701843213","article-title":"Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and hodgkin lymphoma: a single institution result of 168 patients","author":"Akhtar","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transci.2025.104244_bib17","doi-asserted-by":"crossref","unstructured":"Bensinger W., Appelbaum F., Rowley S., Storb R., Sanders J., Lilleby K., et al. Factors That Influence Collection and Engraftment of Autologous Peripheral-Blood Stem Cells. 1995.","DOI":"10.1200\/JCO.1995.13.10.2547"},{"key":"10.1016\/j.transci.2025.104244_bib18","unstructured":"Haas R., Mi R., Fruhauf S., Goldschmidt H., Witt B., Flentje M., et al. Patient Characteristics Associated with Successful Mobilizing and Autografting of Peripheral Blood Progenitor Cells in Malignant Lymphoma."},{"issue":"9","key":"10.1016\/j.transci.2025.104244_bib19","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"issue":"10192","key":"10.1016\/j.transci.2025.104244_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2025.104244_bib21","doi-asserted-by":"crossref","first-page":"340.e1","DOI":"10.1016\/j.jtct.2023.02.013","article-title":"Stem cell mobilization for multiple myeloma patients receiving Daratumumab-Based induction therapy: a Real- world experience","volume":"29","author":"Thurlapati","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.transci.2025.104244_bib22","first-page":"174.e1","article-title":"Stem cell mobilization yields with Daratumumab- and Lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"10.1016\/j.transci.2025.104244_bib23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"Wuchter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.transci.2025.104244_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000525565","article-title":"Risk factors and outcomes of stem cell mobilization failure in multiple myeloma patients","volume":"50","author":"Hsu","year":"2023","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"10.1016\/j.transci.2025.104244_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.blre.2014.01.001","article-title":"Advances in stem cell mobilization","volume":"28","author":"Hopman","year":"2014","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.transci.2025.104244_bib26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-017-0051-y","article-title":"Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score","volume":"53","author":"Olivieri","year":"2018","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104244_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103830","article-title":"Overview on novel strategies and current guidelines for hematopoietic stem cell mobilization and collection","volume":"62","author":"Lanza","year":"2023","journal-title":"Transfus Apher Sci"},{"issue":"ement 1","key":"10.1016\/j.transci.2025.104244_bib28","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1182\/blood-2023-190868","article-title":"Incidence, clinical characteristics and risk factors for poor mobilization of hematopoietic stem cells in a Colombian bone marrow transplantation unit: a retrospective cohort study","volume":"142","author":"Cuervo-Sierra","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.transci.2025.104244_bib29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000531936","article-title":"Mobilization and hematopoietic stem cell collection in poor mobilizing patients with lymphoma: final results of the German OPTIMOB study","volume":"50","author":"Kriegsmann","year":"2023","journal-title":"Transfus Med Hemother"},{"issue":"5","key":"10.1016\/j.transci.2025.104244_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.103983","article-title":"Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: a single center real-world experience","volume":"63","author":"Sarmiento","year":"2024","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2025.104244_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.103931","article-title":"Novel approaches for hematopoietic stem cell mobilization and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose","volume":"63","author":"Lanza","year":"2024","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"10.1016\/j.transci.2025.104244_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfus (Paris)"},{"issue":"4","key":"10.1016\/j.transci.2025.104244_bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/trf.15711","article-title":"Increased collection efficiency of CD34+ cells after mobilization with preemptive use of plerixafor followed by leukocytapheresis on the same day","volume":"60","author":"Cid","year":"2020","journal-title":"Transfus (Paris)"},{"issue":"2","key":"10.1016\/j.transci.2025.104244_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ajh.25672","article-title":"Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts","volume":"95","author":"Shah","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.transci.2025.104244_bib35","first-page":"244.e1","article-title":"Low-Dose cyclophosphamide versus Intermediate-High-Dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"10.1016\/j.transci.2025.104244_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tmrv.2022.06.004","article-title":"Comparison between standard and high dose of G-CSF for mobilization of hematopoietic progenitors cells in patients and healthy donors","volume":"36","author":"Garc\u00eda-Garc\u00eda","year":"2022","journal-title":"Transfus Med Rev"},{"issue":"4","key":"10.1016\/j.transci.2025.104244_bib37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/vox.13410","article-title":"Prediction of blood volume to be processed to achieve a target number of CD34+ cells: development, validation and implementation of a formula","volume":"118","author":"Garc\u00eda-Garc\u00eda","year":"2023","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2025.104244_bib38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/10428190701843213","article-title":"Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and hodgkin lymphoma: a single institution result of 168 patients","author":"Akhtar","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"59","key":"10.1016\/j.transci.2025.104244_bib39","first-page":"1","article-title":"New horizons on stem cell cryopreservation through the artificial eyes of CD34+, using modern flow cytometry tools","volume":"59","author":"Lanza","year":"2020","journal-title":"Transfus Apher Sci"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022500182X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022500182X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:33:36Z","timestamp":1765370016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147305022500182X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S147305022500182X"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104244","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mob-Marly: A Latin American experience in hematopoietic stem cell mobilization for autologous transplantation","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104244"}}